Drug intelligence / Profile preview

crotalicidin

Development stage
Preclinical
Modality
Peptides, Recombinant Proteins and Enzymes
01

Overview

Crotalicidin is a cationic antimicrobial peptide (AMP) belonging to the cathelicidin family, originally isolated from the venom gland of the South American rattlesnake *Crotalus durissus terrificus*. It exhibits potent antimicrobial activity against Gram-negative bacteria and pathogenic yeasts, as well as antitumor properties with selective cytotoxicity toward cancer cells. Mechanistically, crotalicidin acts primarily by disrupting cell membranes through electrostatic interactions and intercalation into lipid bilayers, leading to membrane destabilization and cell death. This mechanism underlies both its antibacterial and antitumoral effects. Crotalicidin also demonstrates activity against protozoan parasites such as *Trypanosoma cruzi*, making it a promising template for anti-infective and anticancer drug development[2][3][5][6][7][8]. Fragments derived from crotalicidin (e.g., Ctn[15–34]) retain or enhance these activities while reducing toxicity toward healthy mammalian cells[5].

Other names
Ctncathelicidin-related vipericidinrattlesnake cathelicidin
02

Targets

PS (Phosphatidylserine)

Beyond the preview

Go deeper on crotalicidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on crotalicidin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call